Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2023 | Story André Damons | Photo Supplied
Prof Champion Nyoni and Prof Motlalepula Matsabisa
Prof Champion Nyoni, Senior Researcher in the School of Nursing at the University of the Free State (UFS). Prof Motlalepula Matsabisa, an African traditional medicine expert and Head of the African Medicines Innovations and Technologies Development Platform (AMITD) within the UFS Department of Pharmacology.

Prof Champion Nyoni, Senior Researcher in the School of Nursing at the University of the Free State (UFS), has been appointed to the World Health Organisation (WHO) Academy Standing Advisory Quality Committee – making him the only representative from Africa to serve in this academy.

Another UFS staff member, Prof Motlalepula Matsabisa, an expert on African traditional medicine and Head of the African Medicines Innovations and Technologies Development Platform (AMITD) within the Department of Pharmacology, has also been appointed to serve on a WHO initiative – the WHO Global Centre for Traditional Medicine Editorial Board/Evidence Task Force. His appointment will be effective until the end of December 2023.

Prof Matsabisa will also attend the first WHO Traditional Medicine Global Summit in India in August 2023, after being invited to serve as a member of the Summit External Advisory Group for the WHO Traditional Medicine Global Summit (‘Advisory Group’).

The appointment of Prof Nyoni, who is the current Chairperson of the Board of Directors for the Africa Interprofessional Education Network (AfrIPEN), and Deputy Chair of the Board for Interprofessional.Global a global confederation of interprofessional networks based in the Netherlands – will be effective for two years.

The WHO Academy is a priority initiative of the WHO transformation agenda and will support accelerated learning and skills recognition of staff and external stakeholders to advance the implementation of the WHO's strategic plan and ‘triple billion’ goal: ensuring that by 2023, an additional one billion people benefit from universal health coverage; one billion more are afforded better protection in health emergencies, and one billion more enjoy improved health and well-being.

Work and contribution being recognised

“I feel thrilled about this exciting adventure. I think this is an exciting opportunity in my career to be recognised by an organisation such as the WHO to serve in the capacity of adviser. I think this is a huge feather in my cap, our School of Nursing, and the faculty. My work and contribution are being recognised and this is a good thing. I am hoping to make an impact in this committee and to also learn from it,” says Prof Nyoni.

Even though there is a bit of pressure representing the whole continent, Prof Nyoni believes his experience with global organisations will come in handy. He is ready to take on the challenge, give it his best, and leave a legacy of excellence.

“Due to the complexity of health professions education in our context, our different cultural, geographical, and socio-economic issues, it is truly an interesting concept to actually think of representing an entire region. I have worked in and continue to work in many countries in Africa through various research projects and postgraduate students, which gives one some insight into what is happening in the region, but often one needs to know more.”

Global knowledge centre for traditional medicine

For Prof Matsabisa, who is also the chairperson of the WHO Regional Expert Advisory Committee on Traditional Medicine (REACT), it is always thrilling to be recognised by serving in such world bodies.

The WHO Global Centre for Traditional Medicine (WHO-GCTM) was established in 2022 as a global knowledge centre for traditional medicine to harness the potential of traditional medicine from across the world through modern science and technology in order to improve the health of people and the planet.

“I look at myself most of the time and ask myself what I am doing right to be given such recognition globally. I am, however, always ready and prepared to take such responsibilities and challenges. I feel happy and great knowing that my expertise and experience is recognised so far from home. I will do my best and try not to fail anyone. I will give it my all and put my whole heart into this task,” says Prof Matsabisa.

He looks forward to seeing the WHO develop tools and guidelines that will promote the institutionalisation of traditional medicine and to come up with positive resolutions on how to take traditional medicines forward.

World takes traditional medicine seriously

According to Prof Matsabisa, the world is now taking traditional medicines seriously. The developed world is now serious about using traditional medicines for their daily health needs and consumption. The world is accepting the positive and important role that traditional medicine is playing in our health-care needs and how it is contributing to the health and well-being of people.

“It is unfortunate that, at home, we have sceptics and people still living in the past who are blind to the importance of traditional medicines. The WHO is now seriously taking the lead in giving advice and guidelines on traditional medicines. It makes me very happy to see these significant movements around traditional medicines."

Africa, Prof Matsabisa concludes, still has its natural resources and its indigenous knowledge as the main remaining tools to get the continent into development and economic freedom. If strategic decisions could be made around developments based on the natural resources for local beneficiation and moving away from the ‘thinking about resources’ to a knowledge-based economy, we could take the continent out of poverty, famine, and wars, and redirect resources to development, technical skills development, and wealth generation for all.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept